Novel medical therapies for gastroesophageal reflux disease beyond proton-pump inhibitors.
The control of TLESRs is a novel pharmacologic approach to the treatment of GERD. It is applicable in most reflux patients characterized as having nonerosive disease or patients with mild erosive disease. Currently, only the GABAB agonist baclofen is available for oral therapy, although side effects may be a limiting factor. Future drug development requires a better understanding of the central and peripheral mechanisms controlling TLESRs.